Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eurofarma Laboratorios S.A.
To assess the efficacy and safety of the association of Chlorthalidone 25 mg + amiloride hydrochloride 5 mg (Diupress® Eurofarma) in the treatment of elderly patients with arterial hypertension, compared to Chlorthalidone 25mg (Higroton® Laboratório Novartis) in same presentation form.
Some eligibility criteria:
perform blood and urine tests; ECG (electrocardiogram); ABPM (Ambulatory Blood Pressure Monitoring; Echocardiogram;Doppler Echocardiogram
Age
60–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Systolic blood pressure between 140 mmHg - 159 mmHg
Diastolic blood pressure between 90 mmHg - 99 mmHg
Subject aged ≥ 60 years old
Be able to comply with instructions, attend study follow-up visits and be willing to participate in the research project.
Diagnosis of stage 1 arterial hypertension with no prior treatment more than 120 days or uncontrolled during antihypertensive agent administration.
You may not be if
Any serious or severe clinically significant medical condition.
Psychiatric or neurological diseases
A condition that, as per Principal Investigator's opinion, may interfere with the optimal participation in the study, or that may result in special risk to the patient.
Participation in any other investigational study within 12 months prior to Visit 1.
Known medical history of allergy, hypersensitivity or intolerance to any of the formulation compounds to be used in this study
Routine prior use of diuretics
Oral anticoagulant use
Fast glycemia \> 150 mg/dL
Medical treatment, not related to study, scheduled for the clinical trial duration; except non-serious, controlled comorbidities in current medical follow-up.
Expected onset of additional antihypertensive drug after the study onset
Acute myocardial infarction within last 6 months
Prior decompensated coronary artery disease
Known thyroid, renal or liver dysfunction, at investigator's discretion
